Afatinib Not Recommended Post-CRT for Patients With Squamous Cell Carcinoma of the Head and Neck

Share this content:
Adding afatinib to standard CRT is not recommended for patients with primary unresected, high- or intermediate-risk HNSCC.
Adding afatinib to standard CRT is not recommended for patients with primary unresected, high- or intermediate-risk HNSCC.
The following article features coverage from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Click here to read more of Cancer Therapy Advisor's conference coverage.

Adding afatinib to standard chemoradiation (CRT) therapy does not improve disease-free survival (DFS) vs placebo among patients with squamous cell carcinoma of the head and neck (HNSCC), according to data presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.1

Barbara Burtness, MD, of the Yale Cancer Center in New Haven, Connecticut, present data from the LUX-head and Neck 2 study (ClinicalTrials.gov Identifier: NCT01345669).

The epidermal growth factor receptor (EGFR) is overexpressed in SCCHN, making it a valid treatment target in this setting. Afatinib is an oral agent that inhibits EGFR.

For this phase 3 study, 617 patients with stage III/IVb HNSCC were randomly assigned 2:1 to afatinib (411 patients) or placebo (206 patients). All patients had completed prior CRT with concurrent cisplatin or carboplatin.

The primary endpoint was DFS. At a planned interim analysis, accrual was stopped for futility. DFS was 43.4 months for patients in the afatinib arm vs not reached for placebo.

Recurrence rates were 23% in both groups. The authors noted that “dose reduction of [afatinib] was required in 53% (mostly due to diarrhea, stomatitis). [Treatment] was discontinued due to [adverse events] in [afatinib] 15%, [placebo] 4%.”

RELATED: Phase 1 Pembrolizumab, Cisplatin, and IMRT for Head and Neck Cancer

Subgroup analyses did not provide guidance on benefits for any subgroup of patients. The authors concluded that adding afatinib to standard CRT is not recommended for patients with primary unresected, high- or intermediate-risk HNSCC.

Read more of Cancer Therapy Advisor's coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting by visiting the conference page.

Reference

  1. Burtness B, Haddad RI, Dinis J, et al. LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III tiral of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts). J Clin Oncol. 2017;35(suppl; abstr 6001).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters